Euclidean Capital’s Tenaya Therapeutics TNYA Stock Holding History

Euclidean Capital’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$751K	Hold	1,015,705	–	–	0.17%	10
2026 Q1	$703K	Hold	1,015,705	–	–	0.18%	9
2025 Q4	$723K	Hold	1,015,705	–	–	0.2%	11
2025 Q3	$1.65M	Hold	1,015,705	–	–	0.69%	9
2025 Q2	$621K	Hold	1,015,705	–	–	0.2%	10
2025 Q1	$579K	Hold	1,015,705	–	–	0.22%	10
2024 Q4	$1.45M	Hold	1,015,705	–	–	0.2%	8
2024 Q3	$1.96M	Hold	1,015,705	–	–	0.22%	9
2024 Q2	$3.15M	Hold	1,015,705	–	–	0.4%	8
2024 Q1	$5.31M	Hold	1,015,705	–	–	0.68%	9
2023 Q4	$3.29M	Hold	1,015,705	–	–	0.37%	10
2023 Q3	$2.59M	Buy	1,015,705 +100,000	+11%	+$419K	0.57%	10
2023 Q2	$5.38M	Hold	915,705	–	–	1.38%	10
2023 Q1	$2.61M	Hold	915,705	–	–	2.29%	9
2022 Q4	$1.84M	Hold	915,705	–	–	1.72%	10
2022 Q3	$2.66M	Hold	915,705	–	–	2.47%	8
2022 Q2	$5.16M	Hold	915,705	–	–	4.38%	7
2022 Q1	$10.8M	Hold	915,705	–	–	6.27%	6
2021 Q4	$17.4M	Hold	915,705	–	–	9.87%	4
2021 Q3	$18.9M	Buy	+915,705	New	+$19.7M	9.19%	4

Other funds holding TNYA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

BGM

Burkehill Global Management New York $2.77B AUM 65.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Euclidean Capital's TNYA Position: Q2 2026 in Review

Euclidean Capital held its Tenaya Therapeutics (TNYA) position steady in Q2 2026 at 1,015,705 shares worth $751K. The position accounts for 0.17% of the portfolio, ranked #10.

Euclidean Capital first reported a position in TNYA in Q3 2021 and has held it in 20 quarters since. The position peaked at $18.9M in Q3 2021. 101 funds tracked by Wall St. Rank hold TNYA as of Q2 2026.

Euclidean Capital held 1,015,705 shares of Tenaya Therapeutics worth $751K as of Q2 2026.
Euclidean Capital left its Tenaya Therapeutics share count unchanged in Q2 2026.
Tenaya Therapeutics made up 0.17% of Euclidean Capital's portfolio in Q2 2026, its #10 holding.
Euclidean Capital first reported a position in Tenaya Therapeutics in Q3 2021 and has held it in 20 quarters since.
Euclidean Capital's Tenaya Therapeutics position peaked at $18.9M in Q3 2021.
101 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2026.

Based on Euclidean Capital's 13F filing for Q2 2026, filed 14 Aug 2026.